glp-1 drugs retatrutide Lilly orforglipron oral phase 3 weight loss trial The experimental GLP-1 drug 'reta'

Relationship of serum trimethylamine N-oxide (TMAO) levels with early atherosclerosis in humans

Acute critical illness: GH-stimulating therapies should generally be avoided during acute illness, major surgery recovery, or trauma, as improved GH in these contexts has been associated with increased mortality in ICU settings

Needle gauge matters more than most protocols acknowledge

Unlike tirzepatide, which activates both GLP-1 and GIP receptors, MariTide is a GIPR antagonist antibody/GLP-1R peptide agonist conjugate which means that it activates GLP-1 receptors while blocking GIP responses

S-adenosylmethionine (SAMe) for neuropsychiatric disorders: A clinician-oriented review of research